Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GERN
SELLGeron Corporation · Healthcare · United States · $911M · Avg Vol: $17M/d
27
StockRankGet insider-trade alerts
Q
34
V
28
M
54
P/E (TTM)
—
ROE
-27.1%
D/E
0.5x
Dividend %
—
COMPANY DESCRIPTION
Geron Corporation is a biopharmaceutical company focused on the development of novel therapeutics for hematologic malignancies. Its lead product candidate, imetelstat, targets telomerase, a unique mechanism of action for specific blood cancers. Geron operates in a high-risk, high-reward niche, aiming to address significant unmet medical needs in oncology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.6M | 0.2M | 77.0M | 183.9M | 575.7% | 196.1M | 234.2M | 342.3M | 36.4% |
| EPS | -0.37 | -0.32 | -0.27 | -0.13 | — | -0.11 | — | — | — |
| Shares | 390.3M | 544.9M | 606.4M | 639.9M | +64.0% | 641.5M | — | — | — |
| Debt | 55.8M | 85.9M | 121.7M | 122.0M | 29.8% | 122.1M | — | — | — |
| Equity | 80.0M | 247.9M | 280.3M | 225.9M | 41.3% | — | — | — | — |
| Op CF | -127.4M | -167.7M | -218.6M | -111.0M | — | -126.0M | — | — | — |
| Inv CF | 62.1M | -180.3M | -106.0M | 107.2M | — | — | — | — | — |
| Fin CF | 87.3M | 362.0M | 334.4M | 2.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+28.7%
SMA 50SMA 200
Close
$1.48
RSI (14)
48.9
52W High
$2.01
From 52W High
0.7%
SCORE BREAKDOWN
Quality
34
ROIC
-11.1%35.1
ROE
-27.1%28.2
GP/Assets
21.0%49.7
Op. Margin
-0.5%35.8
FCF/Assets
-16.1%22.7
Piotroski
25.5
Int. Cover
-1.6x34.2
D/E Ratio
0.53x28.8
Current Ratio
6.78x79.4
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-21.2x25.0
P/FCF
—N/A
P/B
4.0x34.1
P/S
4.7x43.4
Div Yield
—N/A
Momentum
54
52W High %
74%60.2
RS 6M
-1%72.6
SMA 50/200
0.94x50.6
EPS Rev 4W
-7.7%4.4
EPS Rev 12W
0.0%56.8
EPS Improve
+155%84.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$911M
P/E (Forward)
24.0x
Gross Margin
61.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GERN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GERN | Geron Corporation(you) | $911M | 27 | SELL |
| AVTX | Avalo Therapeutics, Inc. | $976M | 25 | SELL |
| REPL | Replimune Group, Inc. | $814M | 26 | SELL |
| JANX | Janux Therapeutics, Inc. | $935M | 24 | SELL |
| DSGN | Design Therapeutics, Inc. | $736M | 26 | SELL |
| ANL | Adlai Nortye Ltd. | $805M | 24 | SELL |
| SLDB | Solid Biosciences Inc. | $771M | 25 | SELL |
| STTK | Shattuck Labs, Inc. | $710M | 26 | SELL |
| PHAT | Phathom Pharmaceuticals, Inc. | $912M | 21 | SELL |
| DRUG.CN | Bright Minds Biosciences Inc. | $727M | 24 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%